13,437 Shares in SPDR S&P Biotech ETF $XBI Bought by Hartline Investment Corp

Hartline Investment Corp bought a new position in SPDR S&P Biotech ETF (NYSEARCA:XBI) during the 4th quarter, Holdings Channel reports. The institutional investor bought 13,437 shares of the exchange traded fund’s stock, valued at approximately $1,638,000.

Several other large investors have also made changes to their positions in XBI. Legacy Wealth Managment LLC ID purchased a new position in shares of SPDR S&P Biotech ETF in the 4th quarter worth $32,000. Ballast Advisors LLC purchased a new position in shares of SPDR S&P Biotech ETF in the 4th quarter worth $36,000. Creative Financial Designs Inc. ADV purchased a new position in shares of SPDR S&P Biotech ETF in the 4th quarter worth $39,000. Barnes Dennig Private Wealth Management LLC purchased a new position in shares of SPDR S&P Biotech ETF in the 4th quarter worth $48,000. Finally, Navalign LLC purchased a new position in shares of SPDR S&P Biotech ETF in the 4th quarter worth $48,000.

SPDR S&P Biotech ETF Trading Down 0.8%

Shares of XBI opened at $131.66 on Friday. The firm has a market capitalization of $8.40 billion, a P/E ratio of 11.47 and a beta of 0.85. The stock’s fifty day simple moving average is $129.82 and its 200 day simple moving average is $125.05. SPDR S&P Biotech ETF has a twelve month low of $78.00 and a twelve month high of $139.19.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.